GTP
CRSP icon

Global Thematic Partners’s CRISPR Therapeutics CRSP Stock Holding History

Global Thematic Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-333,304
Closed -$14.1M – 24
2020
Q1 		$14.1M Sell
333,304
-17,082
-5% -$882K 1.14% 41
2019
Q4 		$21.3M Buy
350,386
+5,764
+2% +$315K 1.31% 36
2019
Q3 		$16.2M Sell
344,622
-75,883
-18% -$3.63M 1.13% 37
2019
Q2 		$19.8M Sell
420,505
-48,020
-10% -$1.92M 1.06% 39
2019
Q1 		$16.7M Buy
468,525
+20,045
+4% +$693K 0.78% 45
2018
Q4 		$12.8M Sell
448,480
-48,796
-10% -$1.7M 0.7% 45
2018
Q3 		$22.1M Buy
497,276
+232,362
+88% +$12.2M 0.87% 43
2018
Q2 		$15.6M Sell
264,914
-86,626
-25% -$4.93M 0.57% 50
2018
Q1 		$16.1M Sell
351,540
-281,912
-45% -$11.6M 0.55% 49
2017
Q4 		$14.9M Buy
633,452
+63,611
+11% +$1.21M 0.49% 49
2017
Q3 		$10.2M Buy
+569,841
New +$10.3M 0.33% 55

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Global Thematic Partners's CRSP Position: Q2 2020 in Review

Global Thematic Partners sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 333,304 shares — an estimated $14.1M sold.

Global Thematic Partners first reported a position in CRSP in Q3 2017 and held it in 11 quarters. The position peaked at $22.1M in Q3 2018. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

  • Global Thematic Partners reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Global Thematic Partners sold 333,304 CRISPR Therapeutics shares in Q2 2020, an estimated $14.1M.
  • Global Thematic Partners first reported a position in CRISPR Therapeutics in Q3 2017 and held it in 11 quarters.
  • Global Thematic Partners's CRISPR Therapeutics position peaked at $22.1M in Q3 2018.
  • 276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on Global Thematic Partners's 13F filing for Q2 2020, filed 31 Jul 2020.